Prevention and treatment of oropharyngeal mucositis following cancer therapy - Are there new approaches?

被引:27
作者
Kwong, KKF [1 ]
机构
[1] Chinese Univ Hong Kong, Fac Med, Nethersole Sch Nursing, Sha Tin, Hong Kong, Peoples R China
关键词
cancer therapy; mucositis management; mucositis prevention; review;
D O I
10.1097/00002820-200405000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oropharyngeal mucositis is an acute and distressing toxic effect of chemotherapy and head and neck irradiation. This oral sequela significantly impairs the daily functioning and quality of life of patients. The biological basis of mucositis is quite complex, involving sequential interaction of chemotherapeutic drugs or irradiation on mitosis of proliferating epithelium, a number of cytokines, and elements of oral microbial environment. Various interventions based on biological attenuation have been tested for mucositis. Such interventions have been reviewed elsewhere; however, most reviews focus on biomedical outcomes. Little attention has been paid to mucositis outcomes with oral morbidity or psychosocial aspects. The purpose of this article is to review the current research studies on the prevention and treatment of oropharyngeal mucositis following chemotherapy, radiotherapy, and bone marrow transplantation with an emphasis on biomedical, oral symptomatic, and functional impairment outcomes. In addition, further avenues of mucositis management, including psychotherapeutic intervention and integrated and stage-based treatment approaches are discussed.
引用
收藏
页码:183 / 205
页数:23
相关论文
共 129 条
  • [1] Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy
    Adamietz, IA
    Rahn, R
    Bottcher, HD
    Schafer, V
    Reimer, K
    Fleischer, W
    [J]. SUPPORTIVE CARE IN CANCER, 1998, 6 (04) : 373 - 377
  • [2] AHMED T, 1993, BONE MARROW TRANSPL, V12, P131
  • [3] PSYCHOLOGICAL INTERVENTIONS FOR CANCER-PATIENTS TO ENHANCE THE QUALITY-OF-LIFE
    ANDERSEN, BL
    [J]. JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1992, 60 (04) : 552 - 568
  • [4] Anderson PM, 1998, CANCER, V83, P1433, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1433::AID-CNCR22>3.0.CO
  • [5] 2-4
  • [6] ATTAL M, 1993, BLOOD, V82, P732
  • [7] Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer
    Awidi, A
    Homsi, U
    Kakail, RI
    Mubarak, A
    Hassan, A
    Kelta, M
    Martinez, P
    Sulaiti, S
    Al Qady, A
    Jamhoury, A
    Daniel, M
    Charles, C
    Ambrose, A
    El-Aloosy, AS
    [J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (16) : 2010 - 2014
  • [8] Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions
    Barasch, A
    Peterson, DE
    [J]. ORAL ONCOLOGY, 2003, 39 (02) : 91 - 100
  • [9] REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION
    BEARMAN, SI
    APPELBAUM, FR
    BUCKNER, CD
    PETERSEN, FB
    FISHER, LD
    CLIFT, RA
    THOMAS, ED
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) : 1562 - 1568
  • [10] Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: Oral Mucositis Patient Provider Advisory Board
    Bellm, LA
    Cunningham, G
    Durnell, L
    Eilers, J
    Epstein, JB
    Fleming, T
    Fuchs, HJ
    Haskins, MN
    Horowitz, MM
    Martin, PJ
    McGuire, DB
    Mullane, K
    Oster, G
    [J]. CANCER INVESTIGATION, 2002, 20 (5-6) : 793 - 800